CEO Joshua Brumm was paid $13,116,834 in fiscal year 2025, the 99th percentile of its disclosed peer group (SEC filing 0001628280-26-026282 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$13,116,834 Joshua Brumm total, FY2025 | 99th CEO pay percentile vs peers | 1,000:1 CEO-to-median pay ratio | 98.39% Say-on-pay support, latest vote |
You have just read Crescent Biopharma's Summary Compensation Table. The whole free brief as a PDF, sent in 2 minutes, with every figure cited — then a few short notes on the deeper CBIO reports.
We send the PDF within 2 minutes, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
CBIO's next annual pay disclosure, estimated April 21, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Joshua Brumm | $554,167 | — | $2,381,440 | $9,635,227 | $546,000 | — | — | $13,116,834 |
| Chief Executive Officer & Director | ||||||||
| Jonathan McNeill | 435,417 | — | 1,163,619 | 4,683,542 | 321,750 | — | — | 6,604,328 |
| Chief Operating Officer & President | ||||||||
| Ellie Im | 401,250 | — | 281,347 | 2,666,923 | 312,975 | — | — | 3,662,495 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Joshua Brumm | $13,116,834 | — | — | — |
| Jonathan McNeill | 6,604,328 | — | — | — |
| Ellie Im | 3,662,495 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
How we handle your data → Privacy
This is the complete answer, not a partial one — the list is never padded.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Ellie Im | Chief Medical Officer | $3,662,495 |
| Jonathan McNeill | President | $6,604,328 |
| Joshua Brumm | CEO | $13,116,834 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Alexandra Balcom | Independent Director | $140,466 |
| David Lubner | Independent Director | $294,991 |
| Jonathan Violin, Ph.D | Director | $474,301 |
| Peter Harwin | Independent Director | $151,575 |
| Susan Moran, M.D., MSCE | Independent Director | $136,964 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jonathan McNeill | Option | 78,029 | 13.21 | — |
| Joshua Brumm | Option | 180,467 | 13.21 | — |
| Joshua Brumm | RSU | 268,400 | — | 3,183,224 |
| Jonathan McNeill | RSU | 134,200 | — | 1,591,612 |
| Joshua Brumm | RSU | 55,117 | — | 653,688 |
| Jonathan McNeill | RSU | 25,507 | — | 302,513 |
| Ellie Im | RSU | 21,298 | — | 252,594 |
| Joshua Brumm | Option | 345,672 | 13.17 | — |
| Jonathan McNeill | Option | 172,836 | 13.17 | — |
| Ellie Im | Option | 65,190 | 13.21 | — |
Compensation positioning is used to attract and retain key employees for the Company’s continued success and growth, balancing internal and external alignment while considering company strategy, shareholder feedback, tenure, performance, and criticality.
| CEO STI target (% of salary) | NaN% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon Consulting, Inc. |
| Clawback policy | true |
| Anti-hedging | The Insider Trading Policy prohibits any employee, officer, director or other covered person from engaging in short sales, transactions involving publicly traded options or other derivative securities based on the Company's securities, other hedging transactions, margin accounts, pledges, or other inherently speculative transactions with respect to the Company's securities at any time. |
| Anti-pledging | The Insider Trading Policy prohibits any employee, officer, director or other covered person from engaging in pledges of the Company's securities at any time. |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-02 | 18,346,099 | 300,217 | 876 | 98.39% | Passed |
| 2024 | 2024-05-01 | 35,292,808 | 1,881,276 | 75,670 | 94.94% | Passed |
| 2023 | 2023-05-19 | 36,116,823 | 435,570 | 112,283 | 98.81% | Passed |
| 2022 | 2022-05-18 | 27,132,991 | 1,035,554 | 88,527 | 96.32% | Passed |
| 2021 | 2021-05-18 | 31,828,920 | 380,710 | 611,792 | 98.82% | Passed |
| 2020 | 2020-05-22 | 34,250,221 | 1,056,258 | 22,197 | 96.95% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-02 | 98.39%a |
| 2024 | 2024-05-01 | 94.94%b |
| 2023 | 2023-05-19 | 98.81%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 1,000 : 1 |
|---|---|
| CEO total compensation | $13,116,834 |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jonathan Violin, Ph.DNot independent | $24,812 | $192,566 | $106,923 | — | $150,000 | $474,301 |
| David LubnerIndependent · Audit Committee · Compensation Committee (Chair) · Nominating and Corporate Governance Committee | 34,569 | 0 | 260,422 | — | 0 | 294,991 |
| Peter HarwinIndependent · Nominating and Corporate Governance Committee (Chair) | 44,652 | 0 | 106,923 | — | 0 | 151,575 |
| Alexandra BalcomIndependent · Audit Committee (Chair) · Compensation Committee | 33,543 | 0 | 106,923 | — | 0 | 140,466 |
| Susan Moran, M.D., MSCEIndependent | 30,041 | 0 | 106,923 | — | 0 | 136,964 |
| Joshua BrummEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 6,000 / 5,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $167,617 |
| Equity awards (grant-date value) | $192,566 |
| All other compensation | $150,000 |
| Total cost of the board | $510,183 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Crescent Biopharma | 2025 | Joshua Brumm | $554,167 | $2,381,440 | $9,635,227 | $546,000 | $13,116,834 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Joshua Brumm | DEF 14A | 2026-04-21 | 0001628280-26-026282 | Section “Executive Compensation”. As printed: 13,116,834. Filing ↗ |
| 2 | Section 01, Jonathan McNeill | DEF 14A | 2026-04-21 | 0001628280-26-026282 | Section “Executive Compensation”. As printed: 6,604,328. Filing ↗ |
| 3 | Section 01, Ellie Im | DEF 14A | 2026-04-21 | 0001628280-26-026282 | Section “Executive Compensation”. As printed: 3,662,495. Filing ↗ |
| 4 | Section 07, pay ratio | DEF 14A | 2026-04-21 | 0001628280-26-026282 | Section “CEO Pay Ratio”. As printed: 1000 : 1. Filing ↗ |
| 5 | Section 08, Jonathan Violin, Ph.D | DEF 14A | 2026-04-21 | 0001628280-26-026282 | Section “Director Compensation”. As printed: 474,301. Filing ↗machine: span 312130–312498 |
| 6 | Section 08, David Lubner | DEF 14A | 2026-04-21 | 0001628280-26-026282 | Section “Director Compensation”. As printed: 294,991. Filing ↗machine: span 307059–307427 |
| 7 | Section 08, Peter Harwin | DEF 14A | 2026-04-21 | 0001628280-26-026282 | Section “Director Compensation”. As printed: 151,575. Filing ↗machine: span 304534–304902 |
| 8 | Section 08, Alexandra Balcom | DEF 14A | 2026-04-21 | 0001628280-26-026282 | Section “Director Compensation”. As printed: 140,466. Filing ↗machine: span 301980–302377 |
| 9 | Section 08, Susan Moran, M.D., MSCE | DEF 14A | 2026-04-21 | 0001628280-26-026282 | Section “Director Compensation”. As printed: 136,964. Filing ↗machine: span 309595–309963 |
| 10 | Section 08, Joshua Brumm | DEF 14A | 2026-04-21 | 0001628280-26-026282 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 11 | Section 06, 2026 vote | Form 8-K | 2026-06-03 | 0001628280-26-040051 | Item 5.07 · say-on-pay result. As reported: 98.39% (votes for as printed: 18,346,099). Filing ↗ |
| 12 | Section 06, 2024 vote | Form 8-K | 2024-05-02 | 0001558370-24-006459 | Item 5.07 · say-on-pay result. As reported: 94.94% (votes for as printed: 35,292,808). Filing ↗ |
| 13 | Section 06, 2023 vote | Form 8-K | 2023-05-22 | 0001558370-23-010301 | Item 5.07 · say-on-pay result. As reported: 98.81% (votes for as printed: 36,116,823). Filing ↗ |
| 14 | Section 09b board cost (computed) | Computed | — | — | Cash 167,617 + equity 192,566 + all other 150,000 = 510,183, summed across the director compensation table rows.machine: formula: Σ = 510,183 |
| 15 | Crescent Biopharma (subject), Section 10b CEO total | DEF 14A | 2026-04-21 | 0001628280-26-026282 | CEO total compensation as printed in Crescent Biopharma's own proxy. As printed: 13,116,834. Filing ↗ |